Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77,736 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study.
Wan G, Nguyen N, Leung BW, Rashdan H, Tang K, Roster K, Collier MR, Ugwu-Dike PO, Raval NS, Alexander NA, Jairath R, Phillipps J, Amadife M, Zhang S, Gusev A, Chen ST, Reynolds KL, LeBoeuf NR, Kwatra SG, Semenov YR. Wan G, et al. Among authors: zhang s. J Am Acad Dermatol. 2024 Feb;90(2):418-420. doi: 10.1016/j.jaad.2023.09.082. Epub 2023 Oct 13. J Am Acad Dermatol. 2024. PMID: 37838257 No abstract available.
Prediction of early-stage melanoma recurrence using clinical and histopathologic features.
Wan G, Nguyen N, Liu F, DeSimone MS, Leung BW, Rajeh A, Collier MR, Choi MS, Amadife M, Tang K, Zhang S, Phillipps JS, Jairath R, Alexander NA, Hua Y, Jiao M, Chen W, Ho D, Duey S, Németh IB, Marko-Varga G, Valdés JG, Liu D, Boland GM, Gusev A, Sorger PK, Yu KH, Semenov YR. Wan G, et al. Among authors: zhang s. NPJ Precis Oncol. 2022 Oct 31;6(1):79. doi: 10.1038/s41698-022-00321-4. NPJ Precis Oncol. 2022. PMID: 36316482 Free PMC article.
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.
Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, Raval N, Seo J, Alexander NA, Jairath R, Phillipps J, Leung BW, Roster K, Chen W, Zubiri L, Boland G, Chen ST, Tsao H, Demehri S, LeBoeuf NR, Reynolds KL, Yu KH, Gusev A, Kwatra SG, Semenov YR. Zhang S, et al. medRxiv [Preprint]. 2023 Jan 18:2023.01.16.23284635. doi: 10.1101/2023.01.16.23284635. medRxiv. 2023. PMID: 36711758 Free PMC article. Updated. Preprint.
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
Zhang S, Tang K, Wan G, Nguyen N, Lu C, Ugwu-Dike P, Raval N, Seo J, Alexander NA, Jairath R, Phillipps J, Leung BW, Roster K, Chen W, Zubiri L, Boland G, Chen ST, Tsao H, Demehri S, LeBoeuf NR, Reynolds KL, Yu KH, Gusev A, Kwatra SG, Semenov YR. Zhang S, et al. J Am Acad Dermatol. 2023 May;88(5):1024-1032. doi: 10.1016/j.jaad.2022.12.048. Epub 2023 Feb 2. J Am Acad Dermatol. 2023. PMID: 36736626 Free PMC article.
Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: A population-level cohort study.
Leung BW, Collier MR, Tiu BC, Wan G, Nguyen N, Tang K, Zhang S, Chen W, Chen ST, LeBoeuf NR, Semenov YR. Leung BW, et al. Among authors: zhang s. J Am Acad Dermatol. 2023 May;88(5):1215-1218. doi: 10.1016/j.jaad.2022.12.042. Epub 2023 Feb 9. J Am Acad Dermatol. 2023. PMID: 36774303 Free PMC article. No abstract available.
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
Nguyen N, Wan G, Ugwu-Dike P, Alexander NA, Raval N, Zhang S, Jairath R, Phillipps J, Leung B, Roster K, Seo J, Lu C, Tang K, Choi MS, DeSimone MS, Theodosakis N, Amadife M, Cox N, Le TK, Liu F, Chen W, Bai X, Boland G, Liu D, Hurlbert MS, LeBoeuf N, Reynolds KL, Yu KH, Tsao H, Asgari M, Gusev A, Kwatra SG, Semenov YR. Nguyen N, et al. Among authors: zhang s. J Am Acad Dermatol. 2023 Jun;88(6):1308-1316. doi: 10.1016/j.jaad.2023.02.014. Epub 2023 Feb 22. J Am Acad Dermatol. 2023. PMID: 36828138 Free PMC article.
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
Leung BW, Wan G, Nguyen N, Rashdan H, Zhang S, Chen W, Cohen S, Boland GM, Sullivan RJ, Fadden RM, Kaufman HL, Kwatra SG, LeBoeuf NR, Semenov YR. Leung BW, et al. Among authors: zhang s. J Am Acad Dermatol. 2023 Jun;88(6):1265-1270. doi: 10.1016/j.jaad.2023.02.017. Epub 2023 Mar 21. J Am Acad Dermatol. 2023. PMID: 36944564 Free PMC article.
Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study.
Wan G, Nguyen N, Leung BW, Rashdan H, Tang K, Roster K, Collier MR, Ugwu-Dike PO, Raval NS, Alexander NA, Jairath R, Phillipps J, Amadife M, Zhang S, Gusev A, Chen ST, Reynolds KL, LeBoeuf NR, Kwatra SG, Semenov YR. Wan G, et al. Among authors: zhang s. medRxiv [Preprint]. 2023 Aug 29:2023.08.28.23294695. doi: 10.1101/2023.08.28.23294695. medRxiv. 2023. PMID: 37693493 Free PMC article. Updated. Preprint.
Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: A multi-institutional cohort study.
Rashdan H, Zhang S, Wan G, Nguyen N, Roster K, Rajeh A, Tang K, Chen W, Moseley C, Chen S, LeBoeuf N, Semenov YR. Rashdan H, et al. Among authors: zhang s. J Am Acad Dermatol. 2024 May;90(5):1080-1083. doi: 10.1016/j.jaad.2024.01.038. Epub 2024 Jan 28. J Am Acad Dermatol. 2024. PMID: 38290617 No abstract available.
77,736 results
You have reached the last available page of results. Please see the User Guide for more information.